GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Ending Cash Position

InflaRx NV (InflaRx NV) Ending Cash Position : $13.92 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Ending Cash Position?

InflaRx NV's Ending Cash Position for the quarter that ended in Dec. 2023 was $13.92 Mil.

InflaRx NV's quarterly Ending Cash Position increased from Jun. 2023 ($21.14 Mil) to Sep. 2023 ($23.16 Mil) but then declined from Sep. 2023 ($23.16 Mil) to Dec. 2023 ($13.92 Mil).

InflaRx NV's annual Ending Cash Position declined from Dec. 2021 ($29.66 Mil) to Dec. 2022 ($17.23 Mil) and declined from Dec. 2022 ($17.23 Mil) to Dec. 2023 ($13.92 Mil).


InflaRx NV Ending Cash Position Historical Data

The historical data trend for InflaRx NV's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Ending Cash Position Chart

InflaRx NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 36.81 31.59 29.66 17.23 13.92

InflaRx NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.23 2.25 21.14 23.16 13.92

InflaRx NV Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

InflaRx NV's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=17.739+-3.815
=13.92

InflaRx NV's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=23.659+-9.735
=13.92


InflaRx NV Ending Cash Position Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


InflaRx NV (InflaRx NV) Business Description

Traded in Other Exchanges
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

InflaRx NV (InflaRx NV) Headlines